186 related articles for article (PubMed ID: 33930801)
1. Overview of piperlongumine analogues and their therapeutic potential.
Zhu P; Qian J; Xu Z; Meng C; Zhu W; Ran F; Zhang W; Zhang Y; Ling Y
Eur J Med Chem; 2021 Aug; 220():113471. PubMed ID: 33930801
[TBL] [Abstract][Full Text] [Related]
2. Piperlongumine (piplartine) as a lead compound for anticancer agents - Synthesis and properties of analogues: A mini-review.
Piska K; Gunia-Krzyżak A; Koczurkiewicz P; Wójcik-Pszczoła K; Pękala E
Eur J Med Chem; 2018 Aug; 156():13-20. PubMed ID: 30006159
[TBL] [Abstract][Full Text] [Related]
3. An Overview of Neolignans of the Genus Piper L.: Isolation Methods and Biological Activities.
Macedo AL; Dos Santos TCC; Valverde AL; Moreira DL; Vasconcelos TRA
Mini Rev Med Chem; 2017; 17(8):693-720. PubMed ID: 27903229
[TBL] [Abstract][Full Text] [Related]
4. Piperlongumine inhibits the proliferation and survival of B-cell acute lymphoblastic leukemia cell lines irrespective of glucocorticoid resistance.
Han SS; Han S; Kamberos NL
Biochem Biophys Res Commun; 2014 Sep; 452(3):669-75. PubMed ID: 25193702
[TBL] [Abstract][Full Text] [Related]
5. Antiplatelet activities of newly synthesized derivatives of piperlongumine.
Park BS; Son DJ; Choi WS; Takeoka GR; Han SO; Kim TW; Lee SE
Phytother Res; 2008 Sep; 22(9):1195-9. PubMed ID: 18697182
[TBL] [Abstract][Full Text] [Related]
6. Piperlongumine induces G2/M phase arrest and apoptosis in cholangiocarcinoma cells through the ROS-JNK-ERK signaling pathway.
Thongsom S; Suginta W; Lee KJ; Choe H; Talabnin C
Apoptosis; 2017 Nov; 22(11):1473-1484. PubMed ID: 28913568
[TBL] [Abstract][Full Text] [Related]
7. Andrographolide and its derivatives: Current achievements and future perspectives.
Zhang H; Li S; Si Y; Xu H
Eur J Med Chem; 2021 Nov; 224():113710. PubMed ID: 34315039
[TBL] [Abstract][Full Text] [Related]
8. Piperlongumine, a constituent of Piper longum L., inhibits rabbit platelet aggregation as a thromboxane A(2) receptor antagonist.
Iwashita M; Oka N; Ohkubo S; Saito M; Nakahata N
Eur J Pharmacol; 2007 Sep; 570(1-3):38-42. PubMed ID: 17618620
[TBL] [Abstract][Full Text] [Related]
9. Pharmacological effects of harmine and its derivatives: a review.
Zhang L; Li D; Yu S
Arch Pharm Res; 2020 Dec; 43(12):1259-1275. PubMed ID: 33206346
[TBL] [Abstract][Full Text] [Related]
10. Piperlongumine as a potential activator of AMP-activated protein kinase in HepG2 cells.
Ryu J; Kim MJ; Kim TO; Huh TL; Lee SE
Nat Prod Res; 2014; 28(22):2040-3. PubMed ID: 24853732
[TBL] [Abstract][Full Text] [Related]
11. Novel non-trimethoxylphenyl piperlongumine derivatives selectively kill cancer cells.
Zhang Y; Ma H; Wu Y; Wu Z; Yao Z; Zhang W; Zhuang C; Miao Z
Bioorg Med Chem Lett; 2017 Jun; 27(11):2308-2312. PubMed ID: 28434764
[TBL] [Abstract][Full Text] [Related]
12. The diverse bioactivity of α-mangostin and its therapeutic implications.
Chavan T; Muth A
Future Med Chem; 2021 Oct; 13(19):1679-1694. PubMed ID: 34410182
[TBL] [Abstract][Full Text] [Related]
13. Piperlongumine, a piper alkaloid targets Ras/PI3K/Akt/mTOR signaling axis to inhibit tumor cell growth and proliferation in DMH/DSS induced experimental colon cancer.
Kumar S; Agnihotri N
Biomed Pharmacother; 2019 Jan; 109():1462-1477. PubMed ID: 30551398
[TBL] [Abstract][Full Text] [Related]
14. Piperlongumine, a piper alkaloid, enhances the efficacy of doxorubicin in breast cancer: involvement of glucose import, ROS, NF-κB and lncRNAs.
Awasthee N; Shekher A; Rai V; Verma SS; Mishra S; Dhasmana A; Gupta SC
Apoptosis; 2022 Apr; 27(3-4):261-282. PubMed ID: 35122181
[TBL] [Abstract][Full Text] [Related]
15. In vitro inhibitory effect of piperlonguminine isolated from Piper longum on human cytochrome P450 1A2.
Song M; Hwang JY; Lee MY; Jee JG; Lee YM; Bae JS; Kim JA; Lee SH; Lee S
Arch Pharm Res; 2014 Aug; 37(8):1063-8. PubMed ID: 24194261
[TBL] [Abstract][Full Text] [Related]
16. Secondary metabolite profiling, cytotoxicity, anti-inflammatory potential and in vitro inhibitory activities of Nardostachys jatamansi on key enzymes linked to hyperglycemia, hypertension and cognitive disorders.
Bose B; Tripathy D; Chatterjee A; Tandon P; Kumaria S
Phytomedicine; 2019 Mar; 55():58-69. PubMed ID: 30668444
[TBL] [Abstract][Full Text] [Related]
17. Design, Synthesis and Pharmacological Evaluation of Novel Piperlongumine derivatives as Potential Antiplatelet Aggregation Candidate.
Wang Y; Wang J; Li J; Zhang Y; Huang W; Zuo J; Liu H; Xie D; Zhu P
Chem Biol Drug Des; 2016 Jun; 87(6):833-40. PubMed ID: 26706668
[TBL] [Abstract][Full Text] [Related]
18. Senolytic activity of piperlongumine analogues: Synthesis and biological evaluation.
Liu X; Wang Y; Zhang X; Gao Z; Zhang S; Shi P; Zhang X; Song L; Hendrickson H; Zhou D; Zheng G
Bioorg Med Chem; 2018 Aug; 26(14):3925-3938. PubMed ID: 29925484
[TBL] [Abstract][Full Text] [Related]
19. Piperlongumine induces ROS mediated cell death and synergizes paclitaxel in human intestinal cancer cells.
Rawat L; Hegde H; Hoti SL; Nayak V
Biomed Pharmacother; 2020 Aug; 128():110243. PubMed ID: 32470748
[TBL] [Abstract][Full Text] [Related]
20. An appraisal on recent medicinal perspective of curcumin degradant: Dehydrozingerone (DZG).
Hampannavar GA; Karpoormath R; Palkar MB; Shaikh MS
Bioorg Med Chem; 2016 Feb; 24(4):501-20. PubMed ID: 26796952
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
